Cytokinetics(US:CYTK) Financial Modeling Prep·2026-02-23 21:00Core Insights - Cytokinetics, Inc. is a biopharmaceutical company focused on developing treatments for cardiovascular diseases, leveraging over 25 years of expertise in muscle biology [1] - The company is set to release its fourth-quarter earnings on February 24, 2026, with investors closely monitoring the anticipated financial results [1] Financial Performance Expectations - Wall Street estimates that Cytokinetics will report an earnings per share (EPS) of -$1.48, with revenue expected to be around $8.02 million, indicating a quarterly loss [2] - The anticipated decline in earnings and revenue compared to the previous year suggests that the company may not achieve an earnings beat in its upcoming report [2] Financial Metrics Analysis - Cytokinetics has a negative price-to-earnings (P/E) ratio of -10.86, indicating it is not currently profitable [3] - The price-to-sales ratio is approximately 95.39, suggesting that investors are paying a high price for each dollar of sales [3] - The enterprise value to sales ratio is around 106.53, reflecting a premium valuation relative to its sales [3] Liquidity and Cash Flow - The company maintains a strong current ratio of 6.88, indicating its ability to cover short-term liabilities with short-term assets [4] - The enterprise value to operating cash flow ratio of -21.46 highlights difficulties in generating positive cash flow from operations [4] - The debt-to-equity ratio of -2.30 suggests more liabilities than equity, which could be a concern for investors [4] Upcoming Earnings Call - The earnings call scheduled for 4:30 PM Eastern Time on February 24 will be crucial for insights into the sustainability of stock price changes and future earnings expectations [5] - Investors can access the live webcast through the company's website, with an archived replay available for six months [5]